BioSpace News Archive

CalciMedica Inc., the CRAC channel company, announced the publication of a research paper describing how bile acid- and ethanol-mediated activation of Orai1 damages pancreatic ductal cells in AP.

SIME Diagnostics, a commercial stage company pioneering rapid intensive care diagnostics, today announced the publication of a peer-reviewed study demonstrating that the company’s point-of-care AI platform can identify ARDS patients with low surfactant concentration.

Exscientia and the University of Oxford Target Discovery Institute announced the formation of Xcellomics – a program designed to source cellular functional assays from the global academic community to develop novel screens and identify targets and therapeutic candidates for unmet medical needs.

Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat cancers and viral diseases, today announced that Charles McDermott, President and Chief Executive Officer of Primmune, will present at the 32nd Annual Oppenheimer Healthcare Conference.

The Business Intelligence Group today announced that it has awarded Abveris a division of Twist Bioscience, a Best Places to Work 2022.

Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, today reported positive clinical data from its recently completed Phase 1 clinical trial evaluating the safety and tolerability of PIPE-307 in healthy volunteers.

Agilent Technologies Inc. announced that the recipient of the 2022 Darlene Solomon Award is Federica Fiorini, Ph.D., a research associate studying metabolomics at the Institute of Biology and Pathology at the Grenoble Alpes University Hospital in France.

Genetic Leap today announced a research collaboration agreement with Astellas Pharma, Inc. to develop novel RNA-targeted small molecule therapeutic candidates against an undisclosed oncology target.

Moderna, Inc. announced that the first participant has been dosed in the Phase 2 study of the Company’s Omicron-specific bivalent booster candidate, which combines Moderna’s Omicron-specific booster candidate and the Moderna COVID-19 vaccine.

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical need conditions, announced today that the Company’s CEO Dr. David Young, will present at the Oppenheimer 32nd Annual Healthcare Conference.